Clinical Edge Journal Scan

Triglyceride-glucose index: A promising atherosclerotic marker in PsA


 

Key clinical point: Triglyceride-glucose (TyG) index demonstrated a positive and robust association with the occurrence of carotid atherosclerosis (CA) and carotid artery plaque (CAP) in patients with psoriatic arthritis, independent of traditional cardiovascular and PsA risk factors.

Major finding: The TyG index was substantially higher in patients with vs without CA (8.82 vs 8.54; P = .002) or CAP (8.88 vs 8.55; P = .001), with significant associations observed between continuous TyG and occurrence of CA (adjusted odds ratio [aOR] 2.69; 95% CI 1.02-7.11) and CAP (aOR 3.61; 95% CI 1.15-11.38).

Study details: Findings are from a cross-sectional study including 165 patients with confirmed diagnosis of PsA who underwent carotid ultrasound and had data available for corresponding TyG index.

Disclosures: This study was supported by the National Natural Science Foundation. The authors declared no conflicts of interest.

Source: Xie W et al. Association between triglyceride glucose index and carotid atherosclerosis in patients with psoriatic arthritis. Rheumatology (Oxford). 2023 (Mar 10). Doi: 10.1093/rheumatology/kead100

Recommended Reading

Apremilast safe and effective in biologic-naive patients with early PsA
MDedge Rheumatology
Disease burden is higher in women vs men with psoriatic arthritis
MDedge Rheumatology
New data forecast more oral PDE4 inhibitors for psoriasis
MDedge Rheumatology
FDA approves new formulation of Hyrimoz adalimumab biosimilar
MDedge Rheumatology
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
MDedge Rheumatology
Commentary: Disease activity, JAK inhibitors, and pregnancy risks in PsA, April 2023
MDedge Rheumatology
New 46-week PsA data released for IL-17A inhibitor izokibep
MDedge Rheumatology
Does COVID-19 vaccination worsen disease activity in PsA patients on targeted therapy?
MDedge Rheumatology
Sex-based differences in efficacy and safety of tofacitinib in PsA
MDedge Rheumatology
Real-life study confirms benefits of secukinumab in PsA
MDedge Rheumatology